Respiratory Syncytial Virus (RSV) Infection Clinical Trials

A listing of Respiratory Syncytial Virus (RSV) Infection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Featured trial
RSV Vaccine Study - M2204

Receive up to $1,035 in compensation and study related care to participate in an RSV Vaccine study. If you are 60 years old or older you may be eligible to receive an RSV Vaccine at no cost.Compensation:- Compensation for up to $1,035- Study related care at no costWho may participate …

  • 0 views
  • 02 Aug, 2022
  • 1 location
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life (VAS00006)

lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive

Accepts healthy volunteers
  • 109 views
  • 18 Nov, 2022
  • 25 locations
A Phase IIIb Randomized Open-label Study of Nirsevimab (Versus no Intervention) in Preventing Hospitalizations Due to Respiratory Syncytial Virus in Infants (HARMONIE) (VAS00006)

lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive

Accepts healthy volunteers
  • 0 views
  • 20 Oct, 2022
  • 26 locations
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through …

Accepts healthy volunteers
  • 6 views
  • 23 Oct, 2022
  • 174 locations
MVA-BN-RSV Vaccine Trial

Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults >=60 years of age

Accepts healthy volunteers
  • 56 views
  • 07 Oct, 2022
  • 95 locations
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).

  • 0 views
  • 28 Oct, 2022
  • 95 locations
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract (RSVTx)

This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI

  • 0 views
  • 29 Oct, 2022
  • 71 locations
  • 2 views
  • 28 Oct, 2022
  • 53 locations
Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults (FLUVAC EV-03)

This study assesses the seasonal of influenza vaccine effectiveness in adults hospitalised with laboratory-confirmed influenza through a network of hospitals in France. Also, To better understand the burden of other respiratory viruses such as respiratory syncytial virus (RSV) and SARS-CoV-2 in hospitalized adults, we need to describe and quantify the …

  • 10 views
  • 04 Oct, 2022
  • 1 location
Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers (VAD00001)

The primary objectives of the study are: To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline neutralizing antibody serostatus. To characterize the Respiratory Syncytial Virus (RSV) A serum neutralizing antibody responses to the study …

Accepts healthy volunteers
respiratory syncytial virus vaccines
vaccination
  • 77 views
  • 24 Oct, 2022
  • 4 locations